These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

207 related articles for article (PubMed ID: 21139240)

  • 21. Further evidence of a combined effect of SERTPR and TPH on SSRIs response in mood disorders.
    Serretti A; Cusin C; Rossini D; Artioli P; Dotoli D; Zanardi R
    Am J Med Genet B Neuropsychiatr Genet; 2004 Aug; 129B(1):36-40. PubMed ID: 15274037
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Controlled clinical comparison of paroxetine and fluvoxamine considering the serotonin transporter promoter polymorphism.
    Kato M; Ikenaga Y; Wakeno M; Okugawa G; Nobuhara K; Fukuda T; Fukuda K; Azuma J; Kinoshita T
    Int Clin Psychopharmacol; 2005 May; 20(3):151-6. PubMed ID: 15812265
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A double-blind, randomized, placebo-controlled trial of pindolol augmentation in depressive patients resistant to serotonin reuptake inhibitors. Grup de Recerca en Trastorns Afectius.
    Pérez V; Soler J; Puigdemont D; Alvarez E; Artigas F
    Arch Gen Psychiatry; 1999 Apr; 56(4):375-9. PubMed ID: 10197835
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Percentage reduction of depression severity versus absolute severity after initial weeks of treatment to predict final response or remission.
    Lin CH; Chen CC; Wang FC; Lane HY
    Psychiatry Clin Neurosci; 2013 May; 67(4):265-72. PubMed ID: 23683158
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Attributes of response in depressed patients switched to treatment with duloxetine.
    Sagman D; McIntosh D; Lee MS; Li H; Ruschel S; Hussain N; Granger RE; Lee AC; Raskin J
    Int J Clin Pract; 2011 Jan; 65(1):73-81. PubMed ID: 21078010
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Cortical Thickness Predicts Response Following 2 Weeks of SSRI Regimen in First-Episode, Drug-Naive Major Depressive Disorder: An MRI Study.
    Wu P; Zhang A; Sun N; Lei L; Liu P; Wang Y; Li H; Yang C; Zhang K
    Front Psychiatry; 2021; 12():751756. PubMed ID: 35273524
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Venlafaxine versus fluvoxamine in the treatment of delusional depression: a pilot double-blind controlled study.
    Zanardi R; Franchini L; Serretti A; Perez J; Smeraldi E
    J Clin Psychiatry; 2000 Jan; 61(1):26-9. PubMed ID: 10695642
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Selective serotonin reuptake inhibitors and venlafaxine in pregnancy: Changes in drug disposition.
    Westin AA; Brekke M; Molden E; Skogvoll E; Spigset O
    PLoS One; 2017; 12(7):e0181082. PubMed ID: 28708853
    [TBL] [Abstract][Full Text] [Related]  

  • 29. 5-HT2A gene variants influence specific and different aspects of antidepressant response in Japanese and Italian mood disorder patients.
    Kato M; Zanardi R; Rossini D; De Ronchi D; Okugawa G; Kinoshita T; Colombo C; Serretti A
    Psychiatry Res; 2009 May; 167(1-2):97-105. PubMed ID: 19361869
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Prediction of antidepressant response to milnacipran and fluvoxamine using pharmacogenetical methods].
    Higuchi H
    Nihon Shinkei Seishin Yakurigaku Zasshi; 2010 Apr; 30(2):71-6. PubMed ID: 20491280
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Activation adverse events induced by the selective serotonin reuptake inhibitor fluvoxamine in children and adolescents.
    Reinblatt SP; DosReis S; Walkup JT; Riddle MA
    J Child Adolesc Psychopharmacol; 2009 Apr; 19(2):119-26. PubMed ID: 19364290
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Sertraline treatment of patients with major depressive disorder who failed initial treatment with paroxetine or fluvoxamine.
    Inoue T; Honda M; Kawamura K; Tsuchiya K; Suzuki T; Ito K; Matsubara R; Shinohara K; Ishikane T; Sasaki K; Boku S; Fujisawa D; Ono Y; Koyama T
    Prog Neuropsychopharmacol Biol Psychiatry; 2012 Aug; 38(2):223-7. PubMed ID: 22504727
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Influence of monoamine oxidase A and serotonin receptor 2A polymorphisms in SSRI antidepressant activity.
    Cusin C; Serretti A; Zanardi R; Lattuada E; Rossini D; Lilli R; Lorenzi C; Smeraldi E
    Int J Neuropsychopharmacol; 2002 Mar; 5(1):27-35. PubMed ID: 12057029
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Combination treatment with clomipramine and fluvoxamine: drug monitoring, safety, and tolerability data.
    Szegedi A; Wetzel H; Leal M; Härtter S; Hiemke C
    J Clin Psychiatry; 1996 Jun; 57(6):257-64. PubMed ID: 8666564
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Efficacy and tolerability of citalopram in comparison with fluvoxamine in depressed outpatients: a double-blind, multicentre study. The LUCIFER Group.
    Haffmans PM; Timmerman L; Hoogduin CA
    Int Clin Psychopharmacol; 1996 Sep; 11(3):157-64. PubMed ID: 8923094
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Therapeutic action and efficiency of fevarin (fluvoxamine) in patients with non-psychotic anxious and apathic-adynamic depressions].
    Neznamov GG; Siuniakov SA; Teleshova ES; Dorofeeva OA; Chumakov DB; Davydova IA
    Zh Nevrol Psikhiatr Im S S Korsakova; 2001; 101(8):19-24. PubMed ID: 11552628
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Fluvoxamine versus imipramine and placebo: a double-blind comparison in depressed patients.
    Fabre L; Birkhimer LJ; Zaborny BA; Wong LF; Kapik BM
    Int Clin Psychopharmacol; 1996 Jun; 11(2):119-27. PubMed ID: 8803649
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A comparison of fluvoxamine and fluoxetine in the treatment of major depression.
    Rapaport M; Coccaro E; Sheline Y; Perse T; Holland P; Fabre L; Bradford D
    J Clin Psychopharmacol; 1996 Oct; 16(5):373-8. PubMed ID: 8889909
    [TBL] [Abstract][Full Text] [Related]  

  • 39. CLOCK may predict the response to fluvoxamine treatment in Japanese major depressive disorder patients.
    Kishi T; Kitajima T; Ikeda M; Yamanouchi Y; Kinoshita Y; Kawashima K; Okochi T; Okumura T; Tsunoka T; Ozaki N; Iwata N
    Neuromolecular Med; 2009; 11(2):53-7. PubMed ID: 19347611
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Fluvoxamine. An updated review of its use in the management of adults with anxiety disorders.
    Figgitt DP; McClellan KJ
    Drugs; 2000 Oct; 60(4):925-54. PubMed ID: 11085201
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.